Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.

Choi, Ilseung; Okada, Masaya; Ito, Tomoki

Choi, Ilseung; Okada, Masaya; Ito, Tomoki.

Affiliation

Choi I; Department of Hematology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-Ku, Fukuoka City, Fukuoka, 811-1395, Japan. choi.ilseung.yc@mail.hosp.go.jp.
Okada M; Department of Hematology, Hyogo College of Medicine Hospital, Nishinomiya City, Hyogo, Japan.
Ito T; First Department of Internal Medicine, Kansai Medical University, Hirakata City, Osaka, Japan.

Ann Hematol ; 102(5): 1149-1158, 2023 May.

Article de En | MEDLINE | ID: mdl-36995403

Sujet(s)
Mots clés

B-cell non-Hodgkin's lymphoma; Prior treatment; Yttrium-90 ibritumomab tiuxetan; sIL-2R

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Lymphome malin non hodgkinien / Lymphome B Type d'étude: Observational_studies / Prognostic_studies Limites: Humans / Middle aged Langue: En Journal: Ann Hematol Sujet du journal: HEMATOLOGIA Année: 2023 Type de document: Article Pays d'affiliation: Japon Pays de publication: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google